Abstract:Key PointsCell-free DNA (cfDNA) is released predominantly by cell death into the bloodstream, although active secretion may have a role. Since the discovery of fetal cfDNA in the maternal circulation, cfDNA analysis has been rapidly implemented in clinical practice for noninvasive prenatal testing.Mutations were first detected in cfDNA more than two decades ago, and interest in circulating tumour DNA (ctDNA) as a noninvasive cancer diagnostic has increased considerably with the development of molecular methods that permit the sensitive detection and monitoring of multiple classes of mutation.ctDNA may have utility at almost every stage of the management of patients with cancer, including diagnosis, minimally invasive molecular profiling, treatment monitoring, the detection of residual disease and the identification of resistance mutations. ctDNA analysis may be broadly considered as a tool both for quantitative analysis of disease burden and for genomic analysis.The identification of ctDNA in individuals before a cancer diagnosis, and in presymptomatic individuals, suggests the possibility of ctDNA analysis as a tool for earlier detection and screening. Noninvasive cancer classification or subtyping has also emerged as a possibility, although for early detection, both technical and biological factors introduce challenges to the detection of mutant DNA in plasma and its interpretation.Monitoring multiple mutations in parallel can enhance the sensitivity of ctDNA detection, can be used to assess the clonal evolution of patients' disease and may identify resistance mutations before clinical progression is observed.ctDNA analysis is beginning to transition from the research setting into the clinic. The US Food and Drug Administration and the European Medicines Agency have approved ctDNA tests for specific indications in the absence of evaluable tumour tissue. Analysis of gene panels in plasma has now become available as a potential clinical tool. Large studies are under way to establish the overall performance and clinical utility of such assays when a tumour biopsy is not available for analysis.Potential applications of ctDNA have been demonstrated by a number of proof-of-principle studies. Prospective clinical trials are beginning to assess the clinical utility of ctDNA analysis for molecular profiling and disease monitoring. The increasing acceptance of ctDNA is enabling the field to move from exploratory ctDNA studies towards clinical trials in which ctDNA guides decision-making.In order to fully exploit the potential utility of liquid biopsies, it is essential that the biology of cfDNA and ctDNA is explored further. The mechanisms of release and degradation, and the factors that affect the representation of ctDNA in plasma, are poorly understood. The nature of ctDNA will be clarified through both large, well-annotated clinical studies and in vivo studies in which variables can be controlled.

The feasibility of using mutation detection in ctDNA to assess tumor dynamics

"Liquid biopsy"-ctDNA detection with great potential and challenges.

Advances in Mutant Detection of Circulating Tumor DNA

Circulating tumor DNA analysis for tumor diagnosis

Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques

A comparative study on ctDNA and tumor DNA mutations in lung cancer and benign cases with a high number of CTCs and CTECs

The Detection of Circulating Tumor DNA: from Digitalization to Sequencing

Technical progress in circulating tumor DNA analysis using next generation sequencing

Circulating tumor DNA in liquid biopsy: Current diagnostic limitation

Application of Data Science in Circulating Tumor DNA Detection: A Promising Avenue Towards Liquid Biopsy.

Cell-free Circulating Tumor DNA in Cancer

Application of Circulating Tumor DNA As a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer

Nanotechnology Strategies For The Analysis Of Circulating Tumor Dna: A Review

Emerging ctDNA detection strategies in clinical cancer theranostics

Liquid biopsies come of age: towards implementation of circulating tumour DNA

Circulating tumor cells and DNA as liquid biopsies

Technologies for analysis of circulating tumour DNA: Progress and promise

Application of Circulating Tumor DNA As a Biomarker for Non-Small Cell Lung Cancer

Progress in the Application of Ctdna on the Cancer Diagnosis and Prognosis

Advances in Detection and Clinical Application of Circulating Tumor DNA

The signature of pharmaceutical sensitivity based on ctDNA mutation in eleven cancers.